News

HCC cells
For the treatment of patients with unresectable hepatocellular carcinoma (HCC), the combination of transcatheter arterial chemoembolization (TACE) with iodine [131I] metuximab infusion may improve local efficacy and overall survival when compared with TACE alone, according to an article in Clinics… Read More
kidney
Computed tomography (CT)-guided percutaneous microwave ablation is safe and well-tolerated in patients with renal cell carcinoma (RCC) and achieves nephron preservation similar to existing ablative modalities, according to a study published in the Journal of Vascular and Interventional Radiology.… Read More
HCC liver
A new study found that Y90 radioembolization with glass microspheres given at a boosted dose in patients with large hepatocellular carcinomas (HCCs) may show favorable tumor response. The results, which were published in the Journal of Vascular and Interventional Radiology, also found that the… Read More
re
Percutaneous image-guided core needle biopsies in tumor >2 cm are safe and effective in obtaining tumour genetic material, according to a study published in the European Journal of Cancer. The study looked at procedural data recorded prospectively between December 2011 and March 2016 for a… Read More
HCC cells
A new study that looked at outcomes of surgical resection after yttrium-90 (Y90) transarterial radioembolization (TARE) in patients with hepatocellular carcinoma found that TARE can serve as a safe bridge to resection. The results were published in the Journal of Vascular and Interventional… Read More
Reviewing Studies
Older age or a higher rate of comorbidities with age do not affect survival in metastatic colorectal cancer when patients receive radiofrequency ablation (RFA), high-dose-rate brachytherapy (HDR-BT), or Y90-radioembolization (Y90-RE), according to a study published in BMC Cancer. An institutional… Read More
liver
The mutational status and histopathologic grade of patients with chemorefractory colorectal liver metastases (CRLM) may predict survival after Y90 radioembolization therapy, according to a study published in Oncotarget. Patients with wild-type mutation status along with a well-differentiated tumor… Read More
HCC liver
Using 3D voxel-based dosimetry in patients with hepatocellular carcinoma (HCC) treated by yttrium-90 (90Y) resin microspheres radioembolization, a new study determined that complete  tumor targeting and 90Y dose to tumor are independent factors associated with clinical outcomes. The results were… Read More
Reviewing Studies
Yttrium-90 (90Y) transarterial radioembolization (TARE) around immunotherapy is safe and effective and the combined treatment may improve hepatic progression-free survival (hPFS) and overall survival (OS) in patients with hepatic metastases from uveal melanoma (UM), according to a new study… Read More
tumore cells
In an exploratory case of a patient with metastatic colorectal cancer, a hotspot panel of cancer-associated gene mutations was used to identify tumor-specific mutations. The results, which showed that liquid biopsies can reveal tumor heterogeneity and predict tumor progression, were published in… Read More